Targeting the epidermal growth factor receptor in non-small cell lung cancer

• Verfasst von: Steins, Martin [VerfasserIn]
• Verfasst von: Reinmuth, Niels [VerfasserIn]
• Verfasst von: Bischoff, Helge [VerfasserIn]
• Verfasst von: Kindermann, Markus [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Titel: Targeting the epidermal growth factor receptor in non-small cell lung cancer
• Verf.angabe: Martin B. Steins, Niels Reinmuth, Helge Bischoff, Markus Kindermann, Michael Thomas
• E-Jahr: 2010
• Jahr: November 26 2010
• Umfang: 6 S.
• Fussnoten: Gesehen am 17.11.2023
• Titel Quelle: Enthalten in: Onkologie
• Ort Quelle: Basel : Karger, 1978
• Jahr Quelle: 2010
• Band/Heft Quelle: 33(2010), 12, Seite 704-709
• ISSN Quelle: 1423-0240
• DOI: doi:10.1159/000322214
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1870605322

Abstract

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways like cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of them important features of cancerogenesis and tumour progression. The inhibition of this receptor has been discovered as a suitable pharmaceutical intervention aimed at interrupting tumour activity. In cancer, both monoclonal antibodies and small molecules with anti-tyrosine kinase activity have been assessed in several trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR inhibition in non-small cell lung cancer with emphasis on tyrosine kinase inhibition.